MEDINCELL Stock: -6.71% at Close, Consolidation After Quarterly Surge
MEDINCELL closed Monday at 29.48 euros, down 6.71% from the previous close. This correction follows a rally of 84.48% over the past three months. The movement contrasts with the strength of the general market, with the CAC 40 up 1.32% in the session. With reduced volume, the stock remains up 64.33% over the past year.
The stock closed at 29.48 euros, down 2.18 euros from 31.66 euros on Friday. The 6.71% drop comes in a context of consolidation after a spectacular rise. However, MEDINCELL outperforms the CAC 40, which has advanced 9.77% over twelve months. The capital turnover was 0.47%, a particularly low volume indicating weak liquidity for the session. The stock manages to stay above its 50-day moving average, set at 27.12 euros. The immediate support zone is at 23.20 euros, while short-term resistance remains anchored at 38.46 euros. The volatility measured over a month reaches 26.10%, reflecting recent market fluctuations.
Fundamental Context Remains Strong
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The fundamental context remains supportive for the group. Partner Teva reported on November 5th the commercial progress of UZEDY, the flagship antipsychotic injectable co-developed with MEDINCELL. In the third quarter of 2025, UZEDY generated $43 million in sales, up 24% annually. Since the beginning of the year, cumulative sales have reached $136 million, an increase of 82% over the equivalent period in 2024. Teva is preparing to file for U.S. market approval for olanzapine LAI in the fourth quarter of 2025. This extension represents significant potential: 20 to 30% of patients on oral olanzapine could be candidates for this injectable form. MEDINCELL would be eligible for development milestones estimated at $7 million, as well as mid- to high-single digit royalties and commercial milestones of $105 million in the long term.
Technical Analysis Signals
Technically, the stock shows mixed signals. The Relative Strength Index (RSI) stands at 39, in a neutral zone leaning towards weakness. The MACD displays a bearish divergence, with its line at 1.82 remaining below the signal line at 2.69. Conversely, the stochastic oscillator signals a short-term buying opportunity. The price moves within the Bollinger Bands, ranging between 31.24 euros and 38.82 euros. The long-term trajectory remains intact, with the stock well above its 200-day moving average, set at 18.38 euros.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
